New Technology Spurs on Proteomics

Graphic: Leza BerardoneOne recent morning at the Applied Biosystems proteomics research center in Framingham, Mass., scientist Jason Marchese patiently used a pipettor to place tiny samples onto a 2-inch-by-2-inch plate. He was surrounded by technology as simple as 2-D gel electrophoresis apparatus and as cutting-edge as a high-throughput system that uses automated robotics for multidimensional liquid chromatography separation of proteins and an automated workstation that uses the latest in mass

Written byJennifer Fisher Wilson
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

The only scientist working in a large room filled with machines for proteomics research, Marchese talked about how he can load protein sample onto machines in the afternoon and return the next day to a database full of newly identified proteins. But in spite of major advances like this, inadequate technology still holds back the field of proteomics. Applied Biosystems is just one of a number of biotechnology companies working hard to provide novel tools to identify more quickly and precisely the thousands upon thousands of proteins produced by the human body.

Now that the human genome is mapped, researchers in academia, government, and industry have turned their attention to mapping proteins. And biotechnology companies are responding by developing the needed tools for the job. Already a multimillion-dollar business, proteomics is expected to grow quickly into a multibillion-dollar business, according to market estimates.

"It was important to map the genome, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies